Does Design Therapeutics Inc. (DSGN) Have Insiders Buying Shares?


As of Friday close, Design Therapeutics Inc.’s (NASDAQ:DSGN) stock was down -$0.55, moving down -7.82 percent to $6.48. The average number of shares traded per day over the past five days has been 1,314,500 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.01 fall in that time frame. In the last twenty days, the average volume was 592,695, while in the previous 50 days, it was 487,674.

Since last month, DSGN stock retreated -5.68%. Shares of the company fell to $6.08 on 03/10/23, the lowest level in the past month. A 52-week high of $26.30 was reached on 01/03/23 after having rallying from a 52-week low of $6.08. Since the beginning of this year, DSGN’s stock price has dropped by -36.84% or -$3.78, and marked a new high 1 time. However, the stock has declined by -75.36% since its 52-week high.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


DSGN stock investors should be aware that Design Therapeutics Inc. (DSGN) stock had its last reported insider trading activity 88 days ago on Dec 20. George Simeon, the Director of the company, purchased of 40,000 shares for $8.14 on Dec 20. It resulted in a $325,432 investment by the insider. SR One Capital Fund I Aggregat added 40,000 shares at an average price of $8.14 on Dec 20. The insider now owns 6,526,476 shares following the transaction. On Dec 20, President and CEO Siffert Joao MD bought 6,300 shares at $8.38 apiece. The transaction was valued at $52,762.

Financial Health

In the three months ended December 30, Design Therapeutics Inc.’s quick ratio stood at 33.50, while its current ratio was 33.50, showing that the company is able to pay off its debt. Based on annual data, DSGN earned $67.59 million in gross profit.

While analysts expected Design Therapeutics Inc. to report -$0.34 quarterly earnings, the actual figure was -$0.31 per share, beating the consensus estimate by 8.80%. The liabilities of Design Therapeutics Inc. were 13.83 million at the end of its most recent quarter ended December 30, and its total debt was $3.69 million. The value of shareholders’ equity is $55.94 million.

Technical Picture

This quick technical analysis looks at Design Therapeutics Inc.’s (DSGN) price momentum. With a historical volatility rate of 65.44%, the RSI 9-day stood at 34.13% on 17 March.

With respect to its five-day moving average, the current Design Therapeutics Inc. price is down by -0.15% percent or -$0.01. At present, DSGN shares trade -4.42% below its 20-day simple moving average and -58.54% percent below its 100-day simple moving average. However, the stock is currently trading approximately -31.79% below its SMA50 and -48.08% below its SMA200.

Stochastic coefficient K was 50.67% and Stochastic coefficient D was 64.65%, while ATR was 0.54. Given the Stochastic reading of 26.67% for the 14-day period, the RSI (14) reading has been calculated as 36.68%. As of today, the MACD Oscillator reading stands at -0.03, while the 14-day reading stands at -0.10.

Analyst Ratings

Wedbush launched its rating on Design Therapeutics Inc. (NASDAQ: DSGN) to an Outperform in a note to investors on June 10, 2022. Design Therapeutics Inc. (DSGN) has been rated Overweight by analysts. According to 1 brokerage firm, DSGN is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Design Therapeutics Inc. stock as buy, with 4 recommending it as overweight.

With a median target price of $22.00, the current consensus forecast for the stock is $6.00 – $42.00. Based on these forecasts, analysts predict Design Therapeutics Inc. (DSGN) will achieve an average price target of $22.80.


Please enter your comment!
Please enter your name here